Some in the gene therapy field lament lost time while Capsida kept silent about the brain receptor it was targeting when ...
Company unveils Parkinson's disease associated with GBA mutations (PD-GBA) program; two oral presentations feature new data from Capsida's wholly owned programs in PD-GBA and genetic epilepsy due to ...
Capsida Biotherapeutics Announces Promotion of Rob Murphy to Chief Manufacturing and Quality Officer
Promotion reinforces commitment to advancing our wholly owned gene therapy pipeline and strength of in-house manufacturing capabilities THOUSAND OAKS, Calif., March 12, 2024 /PRNewswire/ -- Capsida ...
Industry veteran added to complement co-founders Nicholas Flytzanis, Ph.D. and Nick Goeden, Ph.D., to build on Company's excellence in next-generation gene therapy science and bolster efforts to ...
Partnership Combines AbbVie's extensive capabilities with Capsida's novel adeno-associated virus (AAV) engineering platform Builds upon the neurodegenerative disease partnership announced in 2021 ...
Preliminary data show next-generation engineered capsids in non-human primates delivered systemically resulted in widespread transduction in up to 68% of neurons across multiple brain regions Data to ...
Foundational research by Capsida and Caltech demonstrates ability to engineer AAVs with improved efficacy over AAV9 to transduce brain in non-human primates Peer-reviewed publication highlights early ...
THOUSAND OAKS, Calif., Jan. 4, 2023 /PRNewswire/ -- Capsida Biotherapeutics Inc. ("Capsida") today announced a multi-year strategic collaboration with Prevail Therapeutics ("Prevail"), a wholly owned ...
NORTH CHICAGO, Ill. and THOUSAND OAKS, Calif., Feb. 23, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Capsida Biotherapeutics Inc. ("Capsida") today announced an expanded strategic collaboration to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results